Skip to content
MARKETS / BALCAO / AWHL
BALCAO · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP

Aspira Women's Health Inc. AWHL

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.2M
▲ 0.4% YoY
$-12.8M
$-7.0M
In brief

What this company does

We own and operate Aspira Labs, Inc., a research and commercial Clinical Laboratory Improvement Amendments of 1988 certified (“CLIA”) laboratory in Texas. Our product pipeline is focused on two areas: endometriosis and ovarian cancer. Our ENDOinform program is focused on developing a multi-marker test that combines serum proteins, micro RNA (“miRNA”) and clinical data (metadata) for the identification of endometriosis. In ovarian cancer, we have developed clinical data to support the use of our OvaWatch test multiple times for the monitoring of an adnexal mass.

Written from the business description in Aspira Women's Health Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 April 2026. Every sentence was checked against that document before publication.

Growth
USD 9.2M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.2 · Net income -12.8
4M8M-20M201020122014201620182020202220242025
Compound annual growth
+4.0%
+14.7%
+15.5%
+14.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−139 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -85.9% · Net -138.7%
-500%-1000%-1500%201020122014201620182020202220242025
ROE
FY2023 · ROE -723.5%
-200%-400%-600%201020122014201620182020202220242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -7.0
-20M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2015 · Dividends — · Net buybacks 1.2
0.4M0.8M2015

Total assetsUSD 5.5M
EquityUSD -6.9M
CashUSD 1.8M
Gross debtUSD 1.3M
Net debtUSD -478,000.00
Current ratio1.17×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B·····0.00.00.00.00.00.0·····
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.37−0.93−1.81−3.85−4.27−0.18−0.18−0.16−0.20−0.29−0.41−0.53−0.42−0.48−1.25−1.83
Dividend / sh $················
Payout %················
ROE %··−723.5−160.9−158.7−194.0−191.8−215.4−292.8−140.5−103.9−83.5−56.1−95.1−237.6−412.3
Shares out B0.040.020.010.010.010.100.100.080.060.050.050.040.040.020.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 79 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image